Adicet Bio, Inc. (Nasdaq: ACET) reported a Q2 FY2026 net loss of $21.4 million on research and development expense of $18.5 million, and the company ended the quarter with $118.2 million in cash, cash equivalents and short-term investments, a balance the company says funds operations into the second half of 2027. The quarter itself is a clinical-stage burn, not a financial event: research and development was down 35 percent year over year because Adicet stopped new lupus patient enrollment while it prepares to dose a confirmed regulatory path into a pivotal trial, and the cash burn of $22.3 million in the quarter tracks almost exactly with the second-half-of-2027 runway statement management reiterated in the August 5 release. The Q2 print matters because the catalyst that reprices the equity is the 22-patient prula-cel lupus nephritis and systemic lupus erythematosus clinical update that Adicet pushed into the third quarter of 2026 from earlier guidance, with a 13-patient subset that has at least 12 months of follow-up; the data package now informs both an FDA-aligned pivotal trial design in lupus nephritis and the planned initiation of a second program in systemic sclerosis later this year. The risk to that sequence is execution: the company has had a workforce reduction in 2025, lost its chief medical officer in mid-August, and is operating with an interim CMO at a moment when it is also starting a pivotal trial in an autoimmune indication where competing allogeneic and autologous CAR-T programs are advancing quickly. Adicet carries 9.36 million basic shares outstanding, 10.75 million weighted-average diluted shares for the quarter, an accumulated deficit of $656.3 million, and a stock that closed at $8.38 on August 14, 2026, valuing the equity at roughly $78 million on basic shares. The next data point that tests the equity is the third-quarter prula-cel 22-patient update; if the lupus nephritis and systemic lupus erythematosus data package holds the depth and durability of the seven-patient interim the company disclosed in October 2025, the equity rerates against a runway that, on the current burn, gives Adicet through the back half of 2027 to translate clinical readouts into either a partnership or a financing.